PRA’s Arjen Akkerman and Suzanne Jansen discuss how Chemistry, Manufacturing and Controls (CMC) services integrated with a clinical setting can help to shorten timelines, whereby clinical safety data may be obtained in an early drug development stage. The authors also compare the differences between the US and EU regarding early clinical drug development.

Accelerated Early Clinical Manufacturing

Explore related content and topics